| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 74.1 | 2.9 |
| Profit before tax | 36.0 | -146.3 |
| Net income | 35.8 | -146.3 |
| EPS (diluted, $ a share) | $0.08 | $-1.06 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +2437.6% |
|---|---|
| Operating margin | 52.1% |
10-Q filed with the SEC, NASDAQ: PGEN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Precigen, Inc.: key numbers
- Share price
- $4.30Close, Nov 16
- Market cap
- $1.54B
- Shares outstanding
- 358.55MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Precigen, Inc.
All →Precigen Financial Results
Precigen reported third quarter 2026 financial results, highlighted by $72.9 million in PAPZIMEOS net revenue, a 37% sequential increase. The company achieved positive cash flow a full quarter ahead of guidance and reported net income of $35.8 million, driven by strong commercial adoption of its RRP treatment.
- Term
- Q3 2026
“Precigen has established an exceptional position of strength, with commercial momentum and a proven strategy driving our next phase of growth. PAPZIMEOS has transformed treatment for adults with RRP, with well over 500 patients initiating treatment and 300 of them having completed treatment demonstrating recognition as the first-line standard of care.”
Helen Sabzevari, PhD, President and CEO of Precigen
“PAPZIMEOS net revenue grew 37% quarter-over-quarter to $72.9 million, demonstrating the strength of our commercial execution and growing demand for the first FDA-approved therapy for adults with RRP.”
Phil Tennant, Chief Commercial Officer of Precigen